Overview
- 18 inspections across 18 sites are on record.
- 2 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2014-03-25.
At a glance
Inspections
18
Sites
18
Observations
2
Career since
May 2009
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Novartis Pharma Stein AG | 25 Mar 2014 | Human Drugs | |
| GlaxoSmithKline LLC | 23 Aug 2013 | Human Drugs | |
| Teva Biotech GmbH | 26 Apr 2013 | Human Drugs | On file |
| Richter Biologics GmbH | 19 Apr 2013 | Human Drugs | On file |
| Richter Biologics GmbH | 16 Apr 2013 | Human Drugs | On file |
Sites inspected
Novartis Pharma Stein AGStein Ag, Switzerland1 insp.
GlaxoSmithKline LLCConshohocken, United States1 insp.
Teva Biotech GmbHUlm, Germany1 insp.
Richter Biologics GmbHHamburg, Germany1 insp.
Richter Biologics GmbHBovenau, Germany1 insp.
Co-investigators
Investigators who share inspections with this person.
Regina T Brown1 shared
Xiaokuang Lai1 shared
Thomas A Peter1 shared
Seneca D Toms1 shared
Lakshmi Ran Narasimhan1 shared
Mary E Farbman1 shared
Nancy G Schmidt1 shared
Bo Chi1 shared
Full investigator report
Get the verbatim findings behind Kalavati C Suvarna's 2 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site